Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial [PDF]
Lancet Neurology, The, 2023 BackgroundNarcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for ...
yves Dauvilliers, Giuseppe Plazzi
exaly +3 more sources
Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database [PDF]
Frontiers in PharmacologyObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou +5 more
doaj +2 more sources
Histamine H3 receptor inverse agonists/antagonists influence intra-regional cortical activity and inter-regional synchronization during resting state: an exploratory cortex-wide imaging study in mice [PDF]
Molecular BrainThe histaminergic system plays a key role in modulating learning and memory, wakefulness, and energy balance. Histamine H3 receptors constitutively inhibit the synthesis and release of histamine and other neurotransmitters. Therefore, H3 receptor inverse
Sentaro Kaita +3 more
doaj +2 more sources
Results in ChemistryWe developed and validated a liquid chromatography technique to determine organic impurities of Pitolisant in Pitolisant film-coated tablets (4.45 mg and 17.8 mg), a medication used to treat excessive daytime drowsiness.
Jayaprakash Kanijam Raghupathi +6 more
doaj +2 more sources
Narcolepsy: a machine learning bibliometric analysis (1996–2024) [PDF]
Frontiers in NeurologyBackgroundNarcolepsy is a rare neurological cause of chronic sleepiness. This study aimed to better understand global narcolepsy through bibliometric analysis.MethodsArticles and reviews on narcolepsy were sourced from the Web of Science Core Collection.
Minheng Zhang +3 more
doaj +2 more sources
Adjuvant Pitolisant in a Case With Early-Onset Schizophrenia
Clinical Neuropharmacology, 2021 Early-onset schizophrenia is notorious for poor prognostication and treatment refractoriness. Child/adolescent psychiatric population, by virtue of age, is at a heightened risk for cardiometabolic risk of atypical antipsychotics. Available pharmacological options are, sorely, too limited to mitigate this risk.The authors are reporting here on an ...
Ahmed Naguy +2 more
openalex +4 more sources
Biomedical TechnologyThe study focuses on developing a new way to deliver the narcolepsy medication pitolisant. Electrospinning was used to make polyvinyl alcohol (PVA) and hyperbranched polyglycerol (HPG) polymers into pitolisant nanofibers (PT-NF).
Karthikeyan Elumalai
exaly +3 more sources
The dual G9a inhibitor and histamine H3 receptor antagonist A-366 improves repetitive and social behaviors and attenuates neuroinflammation in BTBR T + tf/J mice [PDF]
Scientific ReportsAutism spectrum disorder (ASD) is a prevalent neurodevelopmental condition characterized by repetitive behaviors, impaired sociability, and persistent neuroinflammation.
Malak Hajar +3 more
doaj +2 more sources
Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy
Drug Design, Development and Therapy, 2018 Andrea Romigi,1 Giuseppe Vitrani,1 Temistocle Lo Giudice,1 Diego Centonze,1,2 Valentina Franco3 1IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy; 2Department of System Medicine, University of Rome Tor Vergata Rome, Italy; 3IRCCS ...
Andrea Romigi +2 more
exaly +2 more sources
Pharmacokinetics of pitolisant in children and adolescents with narcolepsy
Sleep Medicine, 2019 To evaluate the pharmacokinetic profile and tolerability of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist, in children and adolescents with narcolepsy.This multicenter, open-label, single-dose study of pitolisant 17.8 mg enrolled patients aged 6 through 17 years with a diagnosis of narcolepsy. Blood samples were collected
Michel Lecendreux +6 more
openalex +6 more sources